The market for pyelonephritis treatments presents opportunities in novel drug development, emphasizing advanced ESBL coverage and efficacy under acidic conditions. Key players include Wockhardt and ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

Investigators evaluated stromal content in the tumor microenvironment as a marker for bladder cancer prognosis, including disease-free survival and overall survival.